IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

By V. Shankaran, H. Ikeda, Allen T. Bruce, J. White, P. Swanson, Lloyd J. Old, Robert Schreiber. Nature, 2001

2,659 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/4649eb4ff61e7229d6024e113290a0cffe632736

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Gabrilovich
2. M. Karin
3. S. Grivennikov
4. F. Greten
5. S. Ostrand-Rosenberg
6. Zena Werb
7. M. Smyth
8. A. Steinle

Citations in the corpus

• The STATs of cancer — new molecular targets come of age (2004, background): “In many circumstances, activated STAT1 seems to act in a pro-apoptotic and anti-proliferative manner, and Stat1 -null mice are more prone to tumour development than control”
• Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. (2007, background): “In immunocompetent individuals, immunosurveillance protects against the development of premalignant cells and the proliferation of malignant cells (40).”
• NK cells and cancer immunosurveillance (2008, background): “Interestingly, mice deficient for both RAG2 and STAT1 have been reported to spontaneously develop adenocarcinoma at higher rates as compared with mice deficient only for RAG2, implicating NK cells in tumour immunosurveillance (Shankaran et al., 2001; Dunn et al., 2004; Swann and Smyth, 2007).”
• Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation (2021, background): “Highly immunodeficient mice, which completely lack adaptive immunity, develop high rates of spontaneous and carcinogen-induced cancers (1, 2).”
• Immunity, Inflammation, and Cancer (2010, positive): “Correspondingly, T cell deficiency or disruption of specific cytotoxic mechanisms can render experimental animals more susceptible to spontaneous or chemical carcinogenesis (Shankaran et al., 2001; Swann and Smyth, 2007).”
• Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (2011, result): “Recent data in murine models confirm this original concept and clearly define immune evasion by aberrant cells as playing an important part in the development and progression of tumour”